ShareValue scores for SBTX.LSE: Valuation 56, Quality 37, Growth 64, Health 42.

SkinBioTherapeutics PLC logo

SBTX.LSE
LSE

SkinBioTherapeutics PLC

£0.04(-5.88%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
56
Fair Value

vs London-listed Healthcare stocks

Price vs Value
Quality
37
Weak
Business Strength
Growth
64
Moderate
Revenue & Earnings
Health
42
Moderate
Financial Stability
Price trend
14
Weak
Separate from the four scores

Company Details

About

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.

Score Analysis

AI Investment Thesis

Powered by DeepSeek. For research only. Not financial advice.

Sources:[1][2][3]

SkinBioTherapeutics PLC looks fairly valued against London-listed Healthcare stocks, with P/B of 1.54 lower than 68% of peers and P/S of 2.35 lower than 56% of peers.

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.